TABLE 2.
Parameter estimates and bootstrap medians (95% confidence intervals) for final pharmacokinetic models of nafamostat in patient and ECMO models.
| Parameter | Patient model | ECMO model | ||||
|---|---|---|---|---|---|---|
| Estimate | RSE (%) | Bootstrapmedian (95% CI) | Estimate | RSE (%) | Bootstrap median (95% CI) | |
| Structural model | ||||||
| θCL (L/h) | 189 | 14.9 | 182 (137–242) | 85.2 | 7.82 | 85.2 (73.1–98.9) |
| θGas flow rate_CL | 0.0999 | 16 | 0.101 (0.0603–0.139) | |||
| θV1 (L) | 7.01 | 42.5 | 7.50 (1.53–14.1) | 3.83 | 17.9 | 3.82 (2.68–5.39) |
| θQ (L/h) | 350 a | 46.7 | 46.9 | 46.6 (19.5–109) | ||
| θV2 (L) | 55.0 | 19.2 | 54.0 (28.7–114.3) | 36.8 | 36.4 | 35.2 (15.9–59.6) |
| θGas flow rate_V2 | −0.852 | 31.1 | −0.902 (−2.48–0.4) | |||
| Interindividual variability | ||||||
| ωCL (%) | 61.3 | 13.0 b | 58.2 (32.5–73.7) | 29.5 | 20.9 b | 27.8 (15.7–40.1) |
| ωV1 (%) | 69.5 a | 62.8 a | ||||
| ωQ (%) | 243 a | 134 a | ||||
| ωV2 (%) | 49.2 a | 0.000 a | ||||
| Residual unexplained variability | ||||||
| σProportional error (%) | 28.7 | 13.2 | 28.3 (21.3–35.9) | 30.9 | 12.8 | 30.6 (23.3–38.3) |
RSE, relative standard error; RSE (%) = (standard error/parameter estimate) × 100; CL, total clearance; V1, central volume of distribution; V2, peripheral volume of distribution; Q, intercompartmental clearance between V1 and V2.
a
fixed.
b
RSE (%) for standard deviation = (standard error/variance estimate) × 100/2.